Biogen Idec presents positive interim results from Phase 1b study of investigational Alzheimer’s Disease treatment aducanumab
23 March 2015 | By Victoria White
Biogen Idec has announced data from the Phase 1b study of aducanumab, in which the drug demonstrated positive results in patients with prodromal or mild AD...